Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265499 | 0.90 | RAB9A (0.37) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL4265493 | 0.90 | RAB9A (0.37) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL2025889 | 0.84 | RAB9A (0.33) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL2022151 | 0.84 | RAB9A (0.33) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL2019670 | 0.84 | RAB9A (0.33) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL2019668 | 0.84 | RAB9A (0.33) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL2022153 | 0.84 | RAB9A (0.33) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL2025888 | 0.84 | RAB9A (0.33) | ALDH1A1SMN1; SMN2POLBRAB9ANPC1 | |
| SCHEMBL3512927 | 0.84 | PDE4B (0.35) | GCKALDH1A1SMN1; SMN2POLBRAB9A | |
| SCHEMBL3512925 | 0.84 | PDE4B (0.35) | GCKALDH1A1SMN1; SMN2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20090005391-A1 | Tricyclo Substituted Amides | PROSIDION LIMITED (GB) | 2009-01-01 | — | — | US | disclosed |
| EP-1948644-A1 | TRICYCLO SUBSTITUTED AMIDES | Prosidion Limited (GB) | 2008-07-30 | — | — | EP | disclosed |
| EP-1594867-B1 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LTD (GB) | 2008-04-09 | — | — | EP | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007051845-A1 | TRICYCLO SUBSTITUTED AMIDES | PROSIDION LTD (GB) | 2007-05-10 | — | — | WO | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005391-A1 | Tricyclo Substituted Amides | GPR119, SLC5A2, SLC5A1 | GCK 44/4885ALDH1A1 1685/4885SMN1; SMN2 2263/4885 |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | GCK 60/4885ALDH1A1 1595/4885SMN1; SMN2 2332/4885 |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | GCK 70/4885ALDH1A1 1846/4885SMN1; SMN2 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.